PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PYRIDOXAL PHOSPHATE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources

Vitamin B6 intake and plasma pyridoxal phosphate concentrations in the first 2 weeks of life.

Plasma pyridoxal phosphate concentrations were measured in 178 hospitalised neonates. A reference interval for neonates less than 7 day old, of 25 to 78 nmol/l has been established. Vitamin B6 intakes did not correlate well with plasma pyridoxal concentrations despite 26 neonates receiving less than the Recommended Allowance (0.3 mg/d) and 19 receiving amounts below which convulsions have been associated (0.1 mg/d). Ten percent of those infants fed breast milk had plasma pyridoxal phosphate levels below the reference interval compared with only 4% of those fed milk formulae. Breast milk from mothers with babies less than 14 days old had a total vitamin B6 contents reference interval of 5 to 40 micrograms/l. Twenty percent of breast milk samples had virtually no vitamin B6 detected.

Bilirubin↗

Pyridoxal phosphate induced association reactions of adrenodoxin and adrenodoxin-reductase.

Pyridoxal phosphate, cofactor of several enzymes, possesses linking properties to induce oligomerization of identical proteins such as adrenodoxin-reductase or adrenodoxin. The capability to get such self-assemblies is slightly lower than that for obtaining the heterologous complex between adrenodoxin-reductase and adrenodoxin which was found to be essential for electron transfer in the cytochrome P450 system. The influence of pyridoxal phosphate on the complex formation between adrenodoxin-reductase and adrenodoxin as well as the oligomerization reaction of the isolated proteins and possible consequences is discussed.

Adrenodoxin↗

Labeling of hemoglobin with pyridoxal phosphate.

The reaction of pyridoxal 5'-phosphate (PLP) with deoxyhemoglobin is confined to 2 residues in the beta chains, i.e. the alpha-amino group of valine 1 and the epsilon-amino group of lysine 82, both of which are located in the polyphosphate binding site. The major product is a hemoglobin in which only the two NH2-terminal amino groups are substituted (symmetric diPLPHb). It is formed by subunit rearrangement of monoPLPHb which is the initial product of the pyridoxylation under anaerobic conditions. TetraPLPHb, with substitutions at lysine 82 and valine 1 of both beta chains is found as a minor component. It results from subunit exchange of asymmetric diPLPHb consisting of one unmodified alpha beta dimer and one which is pyridoxylated at both sites. Anaerobic electrophoresis and oxygenation curves show that this reaction is readily reversed by mixing the tetrasubstituted derivative with unmodified hemoglobin.

Amino Acids↗

Studies on mammalian ribonucleotide reductase inhibition by pyridoxal phosphate and the dialdehyde derivatives of adenosine, adenosine 5'-monophosphate, and adenosine 5'-triphosphate.

Ribonucleotide reductase activity in a partially purified enzyme preparation from Ehrilich tumor cells was inhibited by the dialdehyde derivatives of adenosine, 5-adenylic acid, and adenosine 5-triphosphate (prepared by the periodate oxidation of adenosine 5-adenylic acid, and adenosine 5-triphosphate). The borohydride-reduced derivative of periodate-oxidized adenosine was not inhibitory to the ribonucleotide reductase activity, showing that the aldehyde moiety was important in the inhibitory interactions of these compounds. This suggested the formation of a Schiff base between the dialdehyde derivative and an amino group (presumably, the epsilon-amino group of lysine). Pyridoxal phosphate, which is known to inhibit enzymes that have lysyl residues in the catalytic or allosteric sites, was an inhibitor of ribonucleotide reductase. Pyridoxal, pyridoxamine phosphate, pyridoxamine, and pyridoxine were not inhibitors. Borohydride reduction of the enzyme in the presence of pyridoxal phosphate produced a protein fraction that had little reductase activity remaining. The inhibition by pyridoxal phosphate was not influenced by increasing the substrate concentration (cytidine 5-diphosphate or adenosine 5-diphosphate), but was diminished by increasing the ratio of allosteric effector to pyridoxal phosphate concentrations, suggesting an interaction of pyridoxal phosphate at the regulatory site of ribonucleotide reductase. The addition of adenosine 5-triphosphate to the pyridoxal phosphate-enzyme mixture, which was subsequently treated with borohydride, partially prevented the inhibition by pyridoxal phosphate. Heat treatment of the ribonucleotide reductase enzyme preparation in the presence of pyridoxal phosphate protected the enzyme against loss of cytidine 5-diphosphate and adenosine 5-diphosphate reductase activities.

Adenosine↗

Plasma pyridoxal phosphate concentrations and coenzyme stimulation of erythrocyte alanine aminotransferase activities of white and black adolescent girls.

The vitamin B6 status of 96 white and 90 black female adolescents was assessed utilizing plasma pyridoxal phosphate concentrations, coenzyme stimulation of erythrocyte alanine aminotransferase activities, and vitamin B6 intakes. These values were similar for the two race and three age groups. Fifty-eight percent of the girls reported consuming less than 0.02 mg vitamin B6/g protein daily. The mean coenzyme stimulation and pyridoxal phosphate values of the subjects were 13.5% and 45.2 nM. Coenzyme stimulation values greater than 25% were observed in 18% of the girls and values between 16 and 25%, in 23%. Plasma pyridoxal phosphate concentrations less than 34.4 nM were observed in 26% of the girls and values from 34.4 to 40.5 nM, in 14%. Vitamin B6 inadequacy was prevalent among white and black southern adolescent girls participating in this study as indicated by plasma pyridoxal phosphate concentrations, coenzyme stimulation of erythrocyte alanine aminotransferase activities, and vitamin B6 intakes.

Adolescent↗

Stereochemical evidence for the evolution of pyridoxal-phosphate enzymes of various function from a common ancestor.

Several pyridoxal-phosphate-dependent enzymes can convert the bound cofactor to pyridoxamine phosphate. This conversion may be an obligatory part of the normal catalytic sequence, as with transaminases, or may be an abnormal path, inactivating the enzyme. This conversion requires protonation of the C(4)' carbon of the cofactor, which has now been shown to proceed stereospecifically and with the same absolute stereochemistry in seven quite different pyridoxal-phosphate enzymes. We report on one of these, tryptophan synthase B protein. This regularity in protonation stereochemistry suggests a remarkable regularity in the geometry of cofactor binding to the apoenzyme. This regularity is interpreted as evidence for the evolution of this entire family of enzymes from a common progenitor which, through the course of evolution, could not invert its original, arbitrary binding stereochemistry without passing through catalytically inactive conformations.

Biological Evolution↗

Pyridoxal phosphate catalyzed alpha-beta elimination of selenahomolysine.

In the presence of pyridoxal phosphate selenahomolysine undergoes alpha-beta elimination with production of pyruvate, ammonia and selenohomocysteamine. If the reaction occurs in anaerobic conditions the coupling of pyridoxal phosphate with selenohomocysteamine in a tetrahydro-selenazine ring may be detected by the appearance of an absorption band at 320 nm. In the presence of air the autoxidation rate of selenohomocysteamine is too high to allow the detection of the selenazine derivative. The results obtained add to the previously reported ones indicating that selenium- and sulfur-containing aminoacids react in quite the same way in the non enzymic model studied.

Catalysis↗

Effect of substitution of a lysyl residue that binds pyridoxal phosphate in thermostable D-amino acid aminotransferase by arginine and alanine.

Lys-145 of the thermostable D-amino acid aminotransferase, which binds pyridoxal phosphate, was replaced by Ala or Arg by site-directed mutagenesis. Both mutant enzymes were purified to homogeneity; their absorption spectra indicated that both mutant enzymes contained pyridoxal phosphate bound non-covalently. Even though the standard assay method did not indicate any activity with either mutant, addition of an amino donor, D-alanine, to the Arg-145 mutant enzyme led to a slow decrease in absorption at 392 nm with a concomitant increase in absorption at 333 nm. This result suggests that the enzyme was converted into the pyridoxamine phosphate form. The amount of pyruvate formed was almost equivalent to that of the reactive pyridoxal phosphate in the mutant enzyme. Thus, the Arg-145 mutant enzyme is able to catalyze slowly the half-reaction of transamination. Exogenous amines, such as methylamine, had no effect on the half-reaction with the Arg-145 mutant enzyme. In contrast, the Ala-145 mutant enzyme neither underwent the spectral change by addition of D-alanine nor catalyzed pyruvate formation, in the absence of added amine. However, the Ala-145 mutant enzyme catalyzed the half-reaction significantly in the presence of added amine. These findings suggest that a basic amino acid residue, such as lysine or arginine, is required at position 145 for catalysis of the half-reaction. The role of the exogenous amines differs with various active-site mutant enzymes.

Alanine↗

Changes in serum copper and zinc during treatment with anticancer drugs interfering with pyridoxal phosphate.

Hexamethylmelamine, pentamethylmelamine and procarbazine are anticancer drugs known to interfere with pyridoxal phosphate. This paper presents results on copper and zinc serum levels during the treatment with each of these drugs used as single agents. Six NZW rabbits weighing 2.7-4.5 kg were used in these experiments. Hexamethylmelamine and procarbazine were administered by gastric gavage and pentamethylmelamine by intravenous route at the daily doses of 100 mg, 30 mg and 50 mg/kg of body weight respectively for up to four days. Blood samples were collected in metal free tubes at fasting state before and during the treatment. Student's paired t-test was used for statistical analysis. The pretreatment serum copper concentration significantly (p = 0.05) increased and conversely the serum zinc concentration significantly (p = 0.05) decreased during each drug treatment. Consequently the copper/zinc ration significantly increased from 0.32, 0.33 and 0.27 to 1.16, 0.63 and 1.13 for hexamethylmelamine, pentamethylmelamine and procarbazine respectively. These results indicate, that daily administration of three anticancer drugs interfering with pyridoxal phosphate causes changes in serum copper and zinc levels with inversed relationship between both changes.

Altretamine↗

Variability in absorption lag time of pyridoxal phosphate under fasting and pre- and post-meal conditions.

Inter-individual variations in the absorption lag time of pyridoxal phosphate were determined after administration of an enteric-coated tablet (EC) or a plain capsule (PC) to 113 healthy volunteers under fasting, pre-meal, and post-meal conditions. The absorption lag time of pyridoxal phosphate was assessed from the urinary excretion of 4-pyridoxic acid after administration of EC and PC. Significantly larger lag times after administration of both formulations were observed under post-meal conditions than under pre-meal conditions (0.477 +/- 0.315 h versus 0.081 +/- 0.086 h for PC and 1.995 +/- 1.345 h versus 1.064 +/- 1.327 h for EC), indicating that the mean gastric emptying rates of both a solution and a tablet were delayed after food intake. The lag time for PC showed little inter-individual variation with (0-1.2 h) or without food (0-0.25 h), whereas that for EC showed markedly large inter-individual variation, from 0.25 to 2.63 h (median, 1.5 h) in the fasting condition, from 0.25 to > 5.5 h (median 0.25 h) under pre-meal conditions, and from 0.25 to > 5.5 h (median 1.25 h) under post-meal conditions. The effect of food on the gastric emptying rate of a solution appears to be almost uniform, whereas that for a tablet is so unpredictable that a reliable absorption rate for an enteric-coated tablet cannot be expected, particularly under pre- and post-meal conditions.

Absorption↗

ACTH therapy for infantile spasms: a combination therapy with high-dose pyridoxal phosphate and low-dose ACTH.

Combination therapy consisting of high-dose pyridoxal phosphate (40-50 mg/kg/day) and low-dose synthetic ACTH (0.01 mg/kg/day) was prescribed in 28 children with infantile spasms. Monotherapy with pyridoxal phosphate provided excellent seizure control in 3 of the 28 (11%) patients. ACTH was subsequently added to the regimen of the remaining 25 patients. As of 1 month after discontinuing the ACTH treatment, 21 of the 25 (84%) patients had experienced no seizures. The mean interval until seizure control was achieved was 4.1 days after the start of treatment with ACTH. The 21 patients have been monitored for a mean of 34.9 months (range 2-81 months); 6 patients (29%) have had recurrences of infantile spasms, and 10 (48%) have experienced normal development. Fourteen of the 28 patients (50%) have had transient increases in liver enzymes, but none of the patients developed more serious side effects.

Age of Onset↗

Relationship between pyridoxal phosphate and some synthetic oestrogens, gonadotropin and thyroxine in their effects on kynurenine hydrolase and kynurenine aminotransferase enzymes of normal mouse liver.

The interrelationship between pyridoxal phosphate and gonadotropin and thyroxine in their effects on kynurenine metabolism was studied in the whole liver homogenates from male mice. These in vitro studies were planned to investigate the effects of these hormones on the vitamin B6-dependent enzymes, kynurenine aminotransferase and kynurenine hydrolase. It was found that gonadotropin (from serum of pregnant mares) inhibits both enzymes, whereas thyroxine inhibits the kynurenine aminotransaminase enzymes only. There was evidence indicating that pyridoxal phosphate was not the factor directly responsible for the observed inhibition. Increasing concentrations of pyridoxal phosphate were unable to counteract the inhibitory effects of these hormones.

Animals↗

Glycolaldehyde is a precursor of pyridoxal phosphate in Escherichia coli B.

Carbon-labeled glycolaldehyde prepared from [(14)C]serine was used to supply the nutritional requirement of a pyridoxineless auxotroph of Escherichia coli. Pyridoxal phosphate isolated from bacteria so grown was found to have incorporated the radioactive glycolaldehyde with little dilution. The radioactivity which was unincorporated into pyridoxal phosphate was recovered almost entirely in the culture fluid. The results establish for the first time that glycolaldehyde is indeed a natural precursor of pyridoxal phosphate or it is readily converted to such a precursor.

Aldehydes↗

Activation of alanine aminotransferase in serum by pyridoxal phosphate.

Alanine aminotransferase activity in serum increases significantly when serum is incubated with pyridoxal phosphate. The increase depends on the L-alanine concentration in the final assay mixture, being greatest at 800 mmol/liter. Preincubation of 22 normal sera, in a 10:1 ratio with an 8.09 mmol/liter pyridoxal phosphate solution, resulted in an increase in the alanine aminotransferase activity from 10.5 +/- 4.9 U/liter (mean +/- SD) to 28.4 +/- 5.3 U/liter, an increase of 170%. The absolute amount of apoalanine aminotransferase is relatively constant over a wide range of enzyme activities.

Alanine↗

Pyridoxal phosphate enzymes: mechanistic, structural, and evolutionary considerations.

Pyridoxal phosphate (PLP)-dependent enzymes are unrivaled in the diversity of reactions that they catalyze. New structural data have paved the way for targeted mutagenesis and mechanistic studies and have provided a framework for interpretation of those results. Together, these complementary approaches yield new insight into function, particularly in understanding the origins of substrate and reaction type specificity. The combination of new sequences and structures enables better reconstruction of their evolutionary heritage and illuminates unrecognized similarities within this diverse group of enzymes. The important metabolic roles of many PLP-dependent enzymes drive efforts to design specific inhibitors, which are now guided by the availability of comprehensive structural and functional databases. Better understanding of the function of this important group of enzymes is crucial not only for inhibitor design, but also for the design of improved protein-based catalysts.

Enzyme Inhibitors↗

A method for the isolation and identification of pyridoxal phosphate in proteins.

A method for the isolation and identification of covalently bound pyridoxal phosphate (PLP) contained in some enzymatic proteins is presented. The method involves acid hydrolysis of the protein in the presence of phenylhydrazine, separation of the adduct by elution from Sep-Pak C18 cartridges, isolation by HPLC, and either direct analysis by mass spectrometry with direct electron impact or conversion into trimethylsilyl derivatives followed by gas chromatography-mass spectrometry. Under the prescribed conditions of hydrolysis, PLP forms its phenylhydrazone and is released from the protein and hydrolyzed to the phenylhydrazone of pyridoxal, which shows a typical fragmentation in direct electron impact and in gas chromatography-mass spectrometry after silylation. The yield in phenylhydrazone of pyridoxal is on the order of 50% (+/- 5% SE, n = 15) when PLP is added to 10 mg of protein in amounts ranging from 20 to 40 nmol. Analysis of pig plasma benzylamine oxidase by this procedure confirms the presence of covalently bound pyridoxal phosphate in this enzyme.

Amine Oxidase (Copper-Containing)↗

Biochemical studies of pyridoxal and pyridoxal phosphate status and therapeutic trial of pyridoxine in patients with carpal tunnel syndrome.

A number of recent studies report response of patients with carpal tunnel syndrome to pyridoxine treatment. Neurological and biochemical studies were therefore performed on six patients both before and after treatment with pyridoxine for at least 9 weeks. Free pyridoxal, pyridoxal phosphate, and total pyridoxal were assayed in plasma and neutrophils. The pyridoxal status was also estimated by assaying red cell aspartate aminotransferase. No evidence was obtained to suggest that these patients were deficient in either pyridoxal or pyridoxal phosphate. Although four of the patients claimed some partial symptomatic relief, there was no consistent improvement in clinical findings or neurophysiological measurements following pyridoxine treatment.

Adult↗